Business Wire

DEENOVA

20.6.2022 06:02:09 CEST | Business Wire | Press release

Share
Deenova´s France Remarkable and Continued Success Extends to French overseas departments: winning Mayotte, GHPSO and I.N.I. Awards

Deenova today disclosed that it expanded its market dominance in France with another net new UniHA competitive award for its D3 ACCED mechatronic solution at Centre Hospitalier de Mayotte in French overseas departments. Additionally, Deenova announced a new competitive tender win at GHPSO Creil & Senlis also for its market leading D3 ACCED mechatronic robot through its partnership with another premier hospital group, RESAH . Separately, Deenova is pleased to simultaneously report additional add-on sales of its unique ASTUS cabinets and D3 ACCED to existing Deenova customer Institute Nationale des Invalides in Paris, also through its UniHA partnership.

Loïc Bessin , Managing Director of Deenova in France stated: “Bringing together net new business tender wins at Centre Hospitalier de Mayotte and GHPSO Creil & Senlis for our D3 ACCED mechatronic solutions, while at the same time earning the trust of additional sales to previous Deenova ASTUS customers such as Institute Nationale des Invalides is steady evidence of Deenova France unparalleled success in our industry, undoubtedly showing the market a high level of reliable customer satisfaction in France.”

Christophe Jaffuel , Deenova Chief Commercial Officer, added: “A new milestone for Deenova is reached: expansion beyond the European continent, a great ongoing incentive for our sales teams. I am very appreciative for the important and yearly contribution that both UniHA and RESAH ongoing multi-year tender awards means to Deenova in France and now beyond, renewing its past commitment to Deenova market-leading Unit-Dose solutions. I look forward to continuing the outstanding cooperation with UniHA and RESAH in the near future.”

Centre Hospitalier de Mayotte , a public health establishment with 543 beds, is the only hospital in the overseas Department of Mayotte . It is located in the northern part of the Mozambique Channel in the Indian Ocean off the coast of Southeastern Africa. It provides both hospital care and out-patient care with 4 localized care and childbirth centers (North, Centre, South and Petite-Terre) of intermediate level, providing general consultations and a 24-hour medical service and 7 days a week.

GHPSO Creil & Senlis , located just 30 minutes from Paris CDG airport , offers a complete emergency service: Adult, Paediatric and Gyneco-obstetrics with 584 full hospital beds, 46 day hospitalization places, 21 haemodialysis stations, and on the other hand an offer in Follow-up and Rehabilitation Care (SSR) with 32 beds, in accommodation with 73 Long-Term Care Unit beds (USLD), 90 beds in an Accommodation Establishment for Dependent Elderly Persons (EHPAD) and 12 places in Alzheimer's day centre, i.e. a total of 858 beds. The SMUR unit intervenes at the request of the SAMU de l’Oise.

Institute Nationale des Invalides is placed under the supervision of the French Government Ministry of Defense and Veterans Affairs. It is responsible for welcoming veterans who are victims of severe handicaps linked to war wounds. It includes three complementary centers: the Pensioners’ Center, the Post-Traumatic Rehabilitation Center and the Center for Studies and Research on Equipment for the Handicapped. A total of 91 single rooms are fully equipped for patients in the Paris metropolitan area.

UniHA , the Union of Hospitals for Purchasing, is a cooperative of French public hospital buyers created in 2005 by the hospital staff themselves (32 CHU and 20 CH). As of 2022, 1.065 hospitals have joined the UniHA cooperative, with 115 GHT having conducted € 5.6 billion in group purchases in 2021. UniHA is one of the main European buyers in the field of health and one of the first national buyers, all sectors of activity combined. The essential challenge: to provide citizens with the best treatments available, to provide high-quality hospital services, and to preserve equal access to care.

RESAH is a public interest group (GIP) whose objective is to support the pooling and professionalisation of purchases from the health sector, public and private non-profit. It was created in 2007 to support the pooling of hospital purchases for the Ile-de-France region, in collaboration with Achat Hopital.

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova ’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%. Please visit www.deenova.com for additional information on its market leading solutions.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye